UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date of Report (~~Date~~date of earliest event reported): ~~August~~September 1028, 2023

Tengjun Biotechnology Corp.

(Exact ~~Name~~ name of ~~Registrant~~registrant as ~~Specified~~specified in ~~Charter~~its charter)

Nevada	333-169397	27-3042462
(State or other jurisdiction	(Commission File Number)	(~~IRS~~I.R.S. Employer
of incorporation)		Identification ~~No.~~Number)

East Jinze Road and South Huimin Road, Food Industry Economic and Technology Development District, ~~Jinxiang County, Jining City, Shandong Province, China N/A (Address of principal executive offices) (Zip Code)~~

~~Registrant’s telephone~~Jinxiang ~~number~~County, ~~including~~Jining ~~area~~City, ~~code:~~Shandong ~~(86) 0537-8711599~~Province, China

(Address of principal executive offices and zip code)

(86) 0537-8711599

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K ~~filing~~ is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Indicate by~~☐ ~~check~~Soliciting ~~mark~~material ~~whether~~pursuant ~~the~~to ~~registrant is an emerging growth company as defined in~~ Rule ~~405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b~~14a-212 ofunder the ~~Securities~~ Exchange Act ~~of 1934~~ (§17 CFR 240.~~12b~~14a-~~2 of this chapter~~12).

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
None		None		None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Securities registered~~Item ~~pursuant~~5.02 toDeparture ~~Section~~of ~~12(b)~~Directors or Certain Officers; Election of ~~the~~Directors; ~~Act:~~Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~Title~~Effective as of ~~each~~September 28, ~~class~~2023, ~~Trading~~the ~~Symbol~~Board of Directors (sthe “Board”) ~~Name~~of Tengjun Biotechnology Corp (the “Company”) removed Caihong Qu as a member of ~~each~~the ~~exchange~~Board onand ~~which~~the ~~registered~~interim ~~N/A~~CEO ~~N/A~~and ~~N/A~~CFO of the Company, and appointed her as the Secretary of the Company, until the next annual meeting of the Company’s stockholders, and until her successor is elected and qualified or until her prior death, resignation or removal.

~~Item~~Effective as of September ~~4.02~~28, ~~Non-reliance~~2023, onthe ~~Previously~~Board ~~Issued~~appointed ~~Financial~~Ruiming ~~Statements~~Zhou oras a ~~Related~~member ~~Audit~~of ~~Report~~the Board and the CEO and CFO of the Company, until the next annual meeting of the Company’s stockholders, and until his successor is elected and qualified or ~~Completed~~until ~~Interim~~his ~~Review~~prior death, resignation or removal.

OnMr. ~~August~~Ruiming 10Zhou, ~~2023~~age 56, ~~the~~graduated ~~Company’s~~from ~~Board of Directors (~~the ~~“Board”)~~First ~~concluded~~Vocational ~~that~~School ~~the~~of ~~Company’s~~Ba ~~previously issued financial statements~~Meng, ~~contained~~Inner ~~within~~Mongolia. ~~its~~Since ~~Annual~~June ~~Report~~2017, onhe ~~Form~~has ~~10-K~~served ~~for~~as ~~the~~a ~~fiscal~~director at ~~year~~Shandong ~~ended~~Tengjunxiang ~~December~~Biotechnology 31Co., ~~2022,~~Ltd. ~~should~~Mr. noZhou ~~longer~~is ~~be relied~~not ~~upon~~a ~~due~~party to ~~accounting~~any ~~methodology~~transaction ~~errors~~with inthe ~~such~~Company ~~financial statements and~~ that ~~the~~would ~~Board~~require ~~deems~~disclosure under itItem ~~advisable~~404(a) ~~and in the best interests~~ of ~~the~~Regulation ~~Company~~S-K, toand ~~restate~~there ~~the~~are ~~financial~~no ~~statements~~arrangements byor ~~amending~~understandings ~~its~~between ~~annual~~Mr. ~~report~~Zhou onand ~~Form~~any ~~10-K~~other ~~for~~persons ~~the~~pursuant ~~fiscal~~to which ~~year~~he ~~ended~~was ~~December~~appointed ~~31, 2022~~ as ~~soon~~Director asof ~~reasonably~~the ~~practicable~~Company.

~~Item 5.02~~Effective ~~Departure~~as of ~~Directors~~September 29, or2023, ~~Certain~~Huaping ~~Officers;~~Lu ~~Election~~resigned offrom ~~Directors;~~the ~~Appointment~~Board of ~~Certain~~the ~~Officers;~~Company. ~~Compensatory~~Ms. ~~Arrangements~~Lu’s resignation was not as a result of any disagreements with ~~Certain~~the ~~Officers~~Company on any matter relating to its operations, policies or practices.

On August 10, 2023, the Board resolved to appoint Ms. Caihong Qu as a member of the Board and the interim Chief Executive Officer and Chief Financial Officer of the Company, until the next annual meeting of the Corporation’s shareholders, and until her successor is elected and qualified or until her prior disqualification.1

Ms. Qu, aged 48, graduated from Heilongjiang Agricultural Reclamation Teachers College in the PRC and is the legal representative of Jinxiang County Kanglong Water Purification Equipment Co., Ltd. since 2015. Ms. Qu is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between Ms. Qu and any other persons pursuant to which she was appointed as Director, CEO and CFO of the Company. Ms. Qu is the late wife of Mr. Xianchang Ma, our previous Director, CEO and CFO, who passed away on August 3, 2023.SIGNATURES

~~Item~~Pursuant to the requirements ~~9.01~~of ~~Exhibits~~the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunder duly authorized.

104 Inline XBRL

Date: September 29, 2023

	Tengjun Biotechnology Corp.

	By:	/s/ Ruiming Zhou
		Ruiming Zhou
		Chief Executive Officer

~~FORWARD-LOOKING STATEMENTS~~2

This Form 8-K and other reports filed by Registrant from time to time with the Securities and Exchange Commission (collectively, the “Filings”) contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, Registrant’s management as well as estimates and assumptions made by Registrant’s management. When used in the Filings the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan” or the negative of these terms and similar expressions as they relate to Registrant or Registrant’s management identify forward-looking statements. Such statements reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Registrants ability to complete the restatement and correction of the accounting errors described in this Current Report on Form 8-K, the Registrant’s industry, and the Registrant’s operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although Registrant believes that the expectations reflected in the forward-looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 14, 2023

Tengjun Biotechnology Corp. By: /s/ Huaping Lu Name: Huaping Lu Title: Director

Filing Compare · Tengjun Biotechnology Corp.